Clinical trials: Intravenous Infusions
COPD
Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)
A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion (IV) of Zofin for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT05643729
- Testing
- Zofin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- ZEO ScientifiX, Inc.
Alzheimer Disease
A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects
A randomized, double-blind, placebo-controlled, single dose escalation phase 1 study to access the Pharmacokinetics and Pharmacodynamics of Single Intravenous Administration of SHR-1707
- Trial name
- NCT04745104
- Testing
- SHR-1707
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Crohn's Disease
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever.
- Trial name
- AIM-CD (NCT05068284)
- Testing
- ABBV-154
- Where
- 166 sites in United States, Australia and 22 more
- Volunteers
- 176 people
- Sponsor
- AbbVie
Psoriasis
Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis
The primary objective of this study is to compare disease activity, as measured by PASI score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by intravenous infusion every 2 weeks for a total of 8…
- Trial name
- NCT00192452
- Testing
- MEDI-507
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- MedImmune LLC
Human Immunodeficiency Virus (HIV)
Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)
This study will evaluate how safe Budigalimab is and how it moves within the body in adult participants with HIV-1 infection. Budigalimab is an investigational drug being evaluated for the treatment of Human Immunodeficiency…
- Trial name
- NCT04799353
- Testing
- Budigalimab
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 33 people
- Sponsor
- AbbVie
Osteoarthritis, Knee, Osteoarthritis, Hip
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
This is a phase 2 open-label, 6 arms (1 study group and 1 control group for each joint category), randomized control group clinical study with 300 subjects diagnosed with osteoarthritis of knees (n=100), hips (n=100) and…
- Conditions
- Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis Shoulder
- Trial name
- AdMSCs (NCT04448106)
- Testing
- Celltex- AdMSCs
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Celltex Therapeutics Corporation
Healthy
Ceftaroline China Pharmacokinetics Study
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of ceftaroline in Chinese healthy subjects following single and multiple intravenous doses.
- Trial name
- CeftarolineChi (NCT01458743)
- Testing
- Ceftaroline
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Fabry Disease
PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion
Pharmacokinetic/Pharmacodynamic Study of 2 agalsidase beta Formulations in Single Dose Administered to Healthy Volunteers as intravenous infusion, at a concentration of 1 mg/kg
- Trial name
- NCT05343715
- Testing
- Agalsidase beta from Biosidus 1 mg/kg, Fabrazyme (agalsidase beta) 1 mg/kg
- Where
- Argentina
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bio Sidus SA
Cancer, Neuroendocrine Tumors
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid…
- Conditions
- Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma
- Trial name
- NCT01262235
- Testing
- TKM-080301
- Where
- 8 sites in United States
- Volunteers
- 68 people
- Sponsor
- Arbutus Biopharma Corporation
Astrocytoma, Grade IV, Giant Cell Glioblastoma
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide
- Trial name
- CYNK001GBM01 (NCT04489420)
- Testing
- CYNK001-IV, CYNK001-IT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Celularity Incorporated
Diabetes, Infection
Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients
The use of the Percutaneous Isolated Limb Procedure (PILP) which enables the use of existing antibiotic therapies in a more targeted and concentrated fashion in patients with diabetes who have a significant lower limb infection…
- Trial name
- NCT02158442
- Testing
- Percutaneous Isolated Limb Perfusion (PILP) delivery, Timentin
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Osprey Medical, Inc
Influenza
A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
The purpose of this study is to evaluate the safety , tolerability and pharmacokinetics after multiple ascending of HNC042 given to healthy Chinese volunteers, compared to placebo.
- Trial name
- NCT04603989
- Testing
- HNC042 for Injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Acute Decompensated Heart Failure
Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure
The purpose of this study is to evaluate the efficacy and safety of a continuous intravenous (IV) ularitide infusion on the clinical status and outcome of patients with acute decompensated heart failure (ADHF).
- Trial name
- TRUE-AHF (NCT01661634)
- Testing
- Ularitide
- Where
- 163 sites in United States, Argentina and 20 more
- Volunteers
- 2,157 people
- Sponsor
- Cardiorentis
Acute Pain
Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery
The purpose of this study is to determine the effectiveness and safety of single intravenous doses of the kappa opioid agonist CR845 in relieving pain in patients following laparoscopic-assisted hysterectomy surgery.
- Trial name
- NCT00877799
- Testing
- CR845
- Where
- 12 sites in United States
- Volunteers
- 114 people
- Sponsor
- Cara Therapeutics, Inc.
KRAS Mutant Metastatic Colorectal Cancer
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
This is a Phase 1 dose-escalation study with three dose levels to determine the maximum tolerated dose of REOLYSIN® combined with FOLFIRI and bevacizumab.
- Trial name
- NCT01274624
- Testing
- REOLYSIN®, Irinotecan, Leucovorin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Oncolytics Biotech
Renal Impairment
Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment
To investigate the pharmacokinetics (PK) of POL7080 in subjects with renal function impairment after single intravenous (IV) infusion of POL7080
- Trial name
- NCT02110459
- Testing
- POL7080
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Polyphor Ltd.
Healthy Volunteers
Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers
To evaluate the intrapulmonary pharmacokinetics (PK), including epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations, of SPR206 as well as plasma concentrations of SPR206 in healthy adult volunteers.
- Trial name
- NCT04868292
- Testing
- SPR206
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Spero Therapeutics
Congenital Hyperinsulinism
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent…
- Trial name
- NCT02937558
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Xeris Pharmaceuticals
Alzheimer's Disease
A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease
A study to investigate the safety and tolerability of both single and multiple intravenous administration of GSK933776 in patients with Alzheimer's Disease.
- Trial name
- NCT00459550
- Testing
- GSK933776
- Where
- 7 sites in Australia, Norway and 1 more
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Healthy
Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects
Open-label, randomized, crossover clinical trials for single oral dose of 60mg fimasartan and single IV infusion of 30mg fimasartan to evaluate the absolute bioavailability of Kanarb® tablet (fimasartan) in healthy subjects
- Trial name
- NCT01671020
- Testing
- Fimasartan
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd